What is StemSight Oy?
Founded in 2021 by Heli Skottman and Laura Koivusalo, StemSight Oy is a pioneering biotechnology firm dedicated to addressing severe corneal blindness through cutting-edge stem cell therapies. The company's core innovation lies in its ability to manufacture corneal cells using Nobel Prize-winning induced pluripotent stem (iPS) cell technology. This scalable and cost-effective approach aims to revolutionize treatment options for debilitating ocular conditions, offering new hope to patients worldwide. StemSight's commitment to scientific advancement positions it as a key player in the regenerative medicine sector.
How much funding has StemSight Oy raised?
StemSight Oy has raised a total of $2.4M across 1 funding round:
Other Financing Round
$2.4M
Other Financing Round (2025): $2.4M with participation from Business Finland and Voima Ventures
Key Investors in StemSight Oy
Business Finland
Business Finland is a Finnish public entity that provides innovation funding and internationalization services, aiming to boost Finland's competitiveness. They support science-driven ventures with significant growth potential.
Voima Ventures
Voima Ventures is a venture capital firm focused on deep tech investments in the Nordics and Baltics. They specialize in supporting early-stage scientific ventures that address global challenges, providing capital from pre-seed to Series B.
What's next for StemSight Oy?
With this substantial capital infusion, StemSight Oy is poised for significant expansion. The strategic investment will likely fuel further research and development, accelerate clinical trials, and support the scaling of its manufacturing capabilities. The company's focus on transforming vision restoration treatments indicates a trajectory towards market leadership in the ophthalmology and regenerative medicine fields. Future endeavors may include strategic partnerships and broader commercialization efforts to bring their life-changing therapies to a global patient population.
See full StemSight Oy company page
